FGF2 and neoplasm: As further discussed in a following section, an anti-FGF2 diabody was found to inhibit the expression of PD-L1 and the epithelial mesenchymal transition (EMT) of hepatoma cells, suggesting a potential clinical application in inhibiting metastasis and immune escape [22], while a bispecific single-chain diabody targeting c-Met and PD-1 substantially decreased the tumor burden in an HCC model of high c-Met expression [23], which has led to the development of an analog, CAR-T [24].